RecruitingNot ApplicableNCT07473648

Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure Therapy

Sponsor

The Second Hospital of Anhui Medical University

Enrollment

200 participants

Start Date

Sep 1, 2025

Study Type

INTERVENTIONAL

Conditions

Major Depressive Disorder Electroconvulsive Therapy Magnetic Seizure Therapy

Summary

To compare the efficacy and tolerability of Electroconvulsive Therapy (ECT) and Magnetic Seizure Therapy (MST) in patients with major depressive disorder (MDD).

Eligibility

Min Age: 12 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two brain stimulation treatments — electroconvulsive therapy (ECT, commonly known as shock therapy) and magnetic seizure therapy (MST, a newer alternative) — for people with serious mental health conditions. It also includes healthy volunteers for comparison. The study will use brain scans and eye tests to better understand how these treatments work. **You may be eligible if...** - You are between 12 and 80 years old - You have a diagnosed psychiatric condition confirmed by two psychiatrists - You are on a stable medication regimen before enrolling - You have been recommended for brain stimulation treatment, OR have visual field problems - OR you are a healthy volunteer with no history of psychiatric or neurological disorders **You may NOT be eligible if...** - You have a serious physical illness - You received brain stimulation treatment in the last 3 months - You are pregnant or might be pregnant - You have metal implants in your body or are claustrophobic - You have eye disease or a history of eye surgery (healthy volunteers only) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEElectroconvulsive Therapy

Electroconvulsive therapy will be administered two to four times a week according to a standardized protocol. Stimulation parameters (including intensity, target location, session number, and duration) will be individualized for each participant based on prior research to ensure targeted and safe delivery within established safety limits. Treatment will continue until the participant meets the protocol-defined response criteria or completes a maximum of 10 sessions.

DEVICEMagnetic Seizure Therapy

Magnetic seizure therapy will be administered two to four times a week according to a standardized protocol. Stimulation parameters (including intensity, target location, session number, and duration) will be individualized for each participant based on prior research to ensure targeted and safe delivery within established safety limits. Treatment will continue until the participant meets the protocol-defined response criteria or completes a maximum of 10 sessions.

OTHERCognitive and Behavioral Assessment

Participants will undergo a series of standardized cognitive tests (e.g., MCCB) and behavioral assessments (e.g., clinical rating scales) at specified time points. This does not constitute a therapeutic intervention but is for the purpose of data collection to establish normative baseline performance.

Locations(1)

Anhui Medical University

Hefei, Anhui, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07473648

Related Trials

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

NCT0710511121 locations

CARED : A Novel Rapid Treatment Paradigm for Depression

NCT075073701 location